Why not performing susceptibility test for trimethoprim-sulphamethoxazole?

Hideharu Hagiya

doi:10.1179/1973947814y.0000000215

Why not performing susceptibility test for trimethoprim-sulphamethoxazole?

Hideharu Hagiya

University Hospital

Research output: Contribution to journal › Letter › peer-review

Original language	English
Pages (from-to)	124-125
Number of pages	2
Journal	Journal of Chemotherapy
Volume	27
Issue number	2
DOIs	https://doi.org/10.1179/1973947814y.0000000215
Publication status	Published - 2014

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Keywords

Antimicrobial susceptibility test (AST)
Breakpoint
Minimum inhibitory concentration (MIC)
Trimethoprim-sulphamethoxazole (TMP-SMZ)

ASJC Scopus subject areas

Oncology
Pharmacology
Pharmacology (medical)
Infectious Diseases

Access to Document

10.1179/1973947814y.0000000215

Cite this

@article{3b7cc3b2a644411ebe7230e82f63994c,

title = "Why not performing susceptibility test for trimethoprim-sulphamethoxazole?",

keywords = "Antimicrobial susceptibility test (AST), Breakpoint, Minimum inhibitory concentration (MIC), Trimethoprim-sulphamethoxazole (TMP-SMZ)",

author = "Hideharu Hagiya",

year = "2014",

doi = "10.1179/1973947814y.0000000215",

language = "English",

volume = "27",

pages = "124--125",

journal = "Journal of Chemotherapy",

issn = "1120-009X",